(RF) Eurazeo - Overview
Sector: Financial Services | Industry: Asset Management | Exchange: PA (France) | Market Cap: 2.504m EUR | Total Return: -39.4% in 12m
Stock
Growth Capital, Buyouts, Mid-Market, Real Estate, Consumer Brands
Total Rating 21
Risk 78
Buy Signal -0.47
Market Cap:
2,889m
Avg Trading Vol: 6.76M EUR
Avg Trading Vol: 6.76M EUR
ATR:
3.84%
Peers RS (IBD): 9.3
Peers RS (IBD): 9.3
Risk 5d forecast
Volatility38.1%
Rel. Tail Risk0.77%
Reward TTM
Sharpe Ratio-1.23
Alpha-49.59
Character TTM
Beta0.797
Beta Downside0.689
Drawdowns 3y
Max DD53.15%
CAGR/Max DD-0.24
Description: RF Eurazeo
February 28, 2026
Eurazeo SE (ticker RF) is a French private-equity and venture-capital firm that deploys growth capital, leveraged buyouts and buy-ins across a broad range of sectors, with a particular focus on smart-city, fintech, consumer-brand and health-care businesses in Europe and the United States. The firm targets medium-sized to large companies, investing €25 m–€250 m per transaction, and also manages real-estate assets in Western Europe.
As of the end of 2024, Eurazeo reported €25.3 bn of assets under management, a 7 % increase year-over-year driven by strong fundraising in its “Growth” and “Buy-out” funds. Digital-transformation spending in Europe is expected to grow at a 9 % CAGR through 2028, underpinning Eurazeo’s emphasis on tech-enabled consumer and health-care firms. In the real-estate segment, office vacancy rates in Paris have fallen to 7.2 %-the lowest level since 2019-supporting the firm’s strategy to acquire and reposition large-scale office and residential assets.
For a deeper look at Eurazeo’s valuation and risk profile, you may want to explore ValueRay’s analysis.
- Global private equity deal flow impacts investment and divestment revenue
- Interest rate hikes affect private equity valuations and fundraising
- Regulatory changes in private equity oversight increase compliance costs
- Real estate market fluctuations influence property investment returns
Piotroski VR‑10 (Strict, 0-10)
2.0
| Net Income: -833.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA 5.19 > 1.0 |
| NWC/Revenue: -254.6% < 20% (prev -12.87%; Δ -241.7% < -1%) |
| CFO/TA 0.00 > 3% & CFO 25.9m > Net Income -833.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.28 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.8m) vs 12m ago -28.33% < -2% |
| Gross Margin: -28.90% > 18% (prev 0.67%; Δ -2.96k% > 0.5%) |
| Asset Turnover: 5.29% > 50% (prev 58.73%; Δ -53.44% > 0%) |
| Interest Coverage Ratio: -17.11 > 6 (EBITDA TTM -583.3m / Interest Expense TTM 35.6m) |
Altman Z''
0.98
| A: -0.14 (Total Current Assets 484.3m - Total Current Liabilities 1.74b) / Total Assets 8.93b |
| B: 0.72 (Retained Earnings 6.41b / Total Assets 8.93b) |
| C: -0.07 (EBIT TTM -608.3m / Avg Total Assets 9.35b) |
| D: 0.0 (Book Value of Equity 0.0 / Total Liabilities 2.04b) |
| Altman-Z'' Score: 0.98 = BB |
Beneish M
| DSRI: none (Receivables none/282.3m, Revenue 494.4m/5.74b) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 0.09 (Revenue 494.4m / 5.74b) |
| TATA: -0.10 (NI -833.8m - CFO 25.9m) / TA 8.93b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of RF shares?
As of March 31, 2026, the stock is trading at EUR 39.54 with a total of 140,699 shares traded.
Over the past week, the price has changed by +1.65%, over one month by -20.63%, over three months by -25.75% and over the past year by -39.41%.
Over the past week, the price has changed by +1.65%, over one month by -20.63%, over three months by -25.75% and over the past year by -39.41%.
Is RF a buy, sell or hold?
Eurazeo has no consensus analysts rating.
What are the forecasts/targets for the RF price?
| ISSUER | TARGET | UP/DOWN |
|---|---|---|
| Wallstreet Target Price | 72.5 | 83.4% |
| Analysts Target Price | - | - |
RF Fundamental Data Overview
March 31, 2026
Market Cap USD = 2.89b (2.50b EUR * 1.1537 EUR.USD)P/S = 640.9638
P/B = 0.3774
Revenue TTM = 494.4m EUR
EBIT TTM = -608.3m EUR
EBITDA TTM = -583.3m EUR
Long Term Debt = 199.1m EUR (from longTermDebt, two quarters ago)
Short Term Debt = 1.36b EUR (from shortTermDebt, two quarters ago)
Debt = 1.63b EUR (from shortLongTermDebtTotal, two quarters ago)
Net Debt = 1.63b EUR (using Total Debt 1.63b, CCE unavailable)
Enterprise Value = 4.13b EUR (2.50b + Debt 1.63b - (null CCE))
Interest Coverage Ratio = -17.11 (Ebit TTM -608.3m / Interest Expense TTM 35.6m)
EV/FCF = -1000.0x (Enterprise Value 4.13b / FCF TTM -2.30m)
FCF Yield = -0.06% (FCF TTM -2.30m / Enterprise Value 4.13b)
FCF Margin = -0.46% (FCF TTM -2.30m / Revenue TTM 494.4m)
Net Margin = -168.6% (Net Income TTM -833.8m / Revenue TTM 494.4m)
Gross Margin = -28.90% ((Revenue TTM 494.4m - Cost of Revenue TTM 637.3m) / Revenue TTM)
Gross Margin QoQ = -71.67% (prev none%)
Tobins Q-Ratio = 0.46 (Enterprise Value 4.13b / Total Assets 8.93b)
Interest Expense / Debt = 2.18% (Interest Expense 35.6m / Debt 1.63b)
Taxrate = 25.0% (EU avg default 25%)
NOPAT = -456.2m (EBIT -608.3m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 0.28 (Total Current Assets 484.3m / Total Current Liabilities 1.74b)
Debt / Equity = 0.25 (Debt 1.63b / totalStockholderEquity, two quarters ago 6.63b)
Debt / EBITDA = -2.80 (negative EBITDA) (Net Debt 1.63b / EBITDA -583.3m)
Debt / FCF = -709.8 (out of range, set to none) (Net Debt 1.63b / FCF TTM -2.30m)
Total Stockholder Equity = 7.42b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.92% (Net Income -833.8m / Total Assets 8.93b)
RoE = -11.24% (Net Income TTM -833.8m / Total Stockholder Equity 7.42b)
RoCE = -7.99% (EBIT -608.3m / Capital Employed (Equity 7.42b + L.T.Debt 199.1m))
RoIC = -5.35% (negative operating profit) (NOPAT -456.2m / Invested Capital 8.53b)
WACC = 5.97% (E(2.50b)/V(4.13b) * Re(8.79%) + D(1.63b)/V(4.13b) * Rd(2.18%) * (1-Tc(0.25)))
Discount Rate = 8.79% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -15.34%
[DCF] Fair Price = unknown (Cash Flow -2.30m)
EPS Correlation: -53.30 | EPS CAGR: -32.19% | SUE: 0.0 | # QB: 0
Revenue Correlation: -58.59 | Revenue CAGR: -64.15% | SUE: 0.02 | # QB: 0
EPS next Year (2026-12-31): EPS=4.82 | Chg7d=-1.984 | Chg30d=-1.984 | Revisions Net=-1 | Growth EPS=+380.2% | Growth Revenue=+32.9%